ScientifyResearch logo
Grant Alerts

GRANT Guide

Home » Grants » Technology Impact Award (cancer immunotherapy)

This opportunity is currently closed.

Sign up for Content Alerts to stay informed when this or related funding opportunities are posted.

Technology Impact Award (cancer immunotherapy)

The Technology Impact Award from the Cancer Research Institute provides seed funding to address the gap between technology development and clinical application of cancer immunotherapies. The Award seeks to encourage collaboration between technology developers and cancer immunotherapy clinicians/researchers to develop innovative platforms that may include bioinformatics, ex vivo or in silico modeling systems, immunological or tumor profiling instrumentation, methods, reagents and assays, to better understand the underlying mechanisms of cancer immunotherapy. Applicants must hold a faculty appointment as a tenure-track assistant professor (or higher rank) at the time of award activation. Applicants at non-profit research institutions worldwide are encouraged to apply. Award provides funding of up to 200,000 USD (direct costs only) for a period of 12-24 months. Letters of intent are due November 15, 2022. Full application closing date is March 15, 2023.

Intended for: Early-career principal investigators|Mid-career researchers|Senior researchers

Discipline: Cancer research|Immuno-oncology|Immunology|Oncology

Sign in with your free account to see important eligibility criteria, including research location, citizenship, legal working rights and deadline/s.

Sign-in for link to funder’s page
Create Grant Alerts

…share with your friends

Related Posts

Search all grants
Logo2

more time for research

About
Us

Funding
Blog & Events

Special
Research Funding

Funding by
Career Stage

Funding by
Subject

Funding by
Location

COPYRIGHT © 2023 SCIENTIFYRESEARCH
Logo2

more time for research

COPYRIGHT © 2023 SCIENTIFYRESEARCH

Sign-up for the
scientifyRESEARCH
monthly research
funding newsletter

You can unsubscribe at any time.